The next big thing in auto-immune therapies: worms. Or so a young California biotech believes. Holoclara is pioneering a new class of medicines derived from intestinal worms to revolutionize the treatment of autoimmune diseases, allergies, and more.
Andrea Choe, CEO at Holoclara
Key Takeaways
Holoclara is developing therapeutics from worm secretions, aiming to modulate the immune system rather than suppress it.
As Eureka moments go, Andrea Choe’s was very 21st century. Choe is the CEO and co-founder of Holoclara, a biotech...
